In this work, we systematically evaluated proteome remodeling driven by well-known oncogenes (c-Myc, EGFR, HER2, AKT, KRAS, BRAF, or MEK) expressed in isogenic models and relevant cancer-derived and patient-derived pancreatic cancer and osteosarcoma. This evidence concerns the gene KRAS and cancer.